| 3.7 0.04 (1.09%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.53 | 1-year : | 5.13 |
| Resists | First : | 3.88 | Second : | 4.4 |
| Pivot price | 3.47 |
|||
| Supports | First : | 3.04 | Second : | 2.53 |
| MAs | MA(5) : | 3.56 |
MA(20) : | 3.5 |
| MA(100) : | 3.75  |
MA(250) : | 3.55 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 68.4 |
D(3) : | 62.1 |
| RSI | RSI(14): 53.7 |
|||
| 52-week | High : | 6.94 | Low : | 1.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRME ] has closed below upper band by 10.8%. Bollinger Bands are 47.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.87 - 3.89 | 3.89 - 3.91 |
| Low: | 3.61 - 3.62 | 3.62 - 3.64 |
| Close: | 3.67 - 3.7 | 3.7 - 3.72 |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Fri, 10 Apr 2026
Prime Medicine (NASDAQ:PRME) Trading Down 6.4% - Here's What Happened - MarketBeat
Tue, 31 Mar 2026
Prime Medicine, Inc. (NASDAQ:PRME) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Fri, 27 Mar 2026
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3% - What's Next? - MarketBeat
Thu, 26 Mar 2026
Prime Medicine (PRME) focuses on liver franchise with $191.4M cash runway - MSN
Tue, 03 Mar 2026
Prime Medicine (Nasdaq: PRME) details 2025 results, cash runway and gene-editing milestones - Stock Titan
Tue, 03 Mar 2026
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 181 (M) |
| Held by Insiders | 1.0438e+008 (%) |
| Held by Institutions | 23.7 (%) |
| Shares Short | 28,080 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.0103e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 800.4 % |
| Return on Equity (ttm) | -40.7 % |
| Qtrly Rev. Growth | 4.63e+006 % |
| Gross Profit (p.s.) | -23.88 |
| Sales Per Share | -56.91 |
| EBITDA (p.s.) | -6.04651e+007 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -163 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 14.03 |
| Dividend | 0 |
| Forward Dividend | 2.681e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|